. .
Merck & Co. . is buying biopharmaceutical company OncoImmune, which reported positive results from a late-stage study of a coronavirus therapy candidate, for $ 425 million in cash.
The acquisition is the latest of the major drug company that has caught up with the most important vaccination and treatment hunt in modern history. Earlier Monday, AstraZeneca PLC and Oxford University said their Covid-19 vaccine was 90% effective in large clinical trials and one shot at preventing infection without serious side effects. . .
Merck & Co. . , OncoImmune, Inc. .
World News – United States – Merck to buy OncoImmune amid a race for Covid-19 treatments
Ref: https://www.wsj.com